MedTrace Logo

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2019-07-31

Study results available
· View outcomes & findings →

Summary

This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine.

Conditions

Interventions

DRUG

Lamotrigine

anticonvulsant medication

DRUG

Ketamine

subanesthetic dose of NMDAR antagonist

DRUG

Riluzole

glutamate release inhibitor

Sponsors & Collaborators

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Sanjay Mathew, MD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-07-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419003 on ClinicalTrials.gov